52.40

1.32% -0.70

After Hours: 52.40

Sanofi Adr (SNY)

Overview News Price History Option Chain Why SNY Down? Discussions Forecast Dividend History

Sanofi Adr stock is traded at $52.40, with a volume of 1.99M. It is down -1.32% in the last 24 hours and up +8.42% over the past month. Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Previous Close:

$53.10

Open:

$52.67

24h Volume:

1.99M

Market Cap:

$131.11B

Revenue:

$50.69B

Net Income/Loss:

$4.95B

P/E Ratio:

16.51

EPS:

3.1735

Net Cash Flow:

$19.70B

1W Performance:

+3.52%

1M Performance:

+8.42%

6M Performance:

+4.51%

1Y Performance:

-2.07%

1D Range:

$52.37

$52.85

52W Range:

$42.63

$55.72

Sanofi Adr Stock (SNY) Company Profile

Name

Sanofi Adr

Sector

Healthcare (1186)

Industry

Drug Manufacturers - General (17)

Phone

Address

Employee

87,994

Twitter

@sanofi

Next Earnings Date

2024-07-25

Latest SEC Filings

SNY's Discussions on Twitter

Sanofi Adr Stock (SNY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight
Jan-16-24	Resumed	UBS	Buy
Dec-05-23	Downgrade	JP Morgan	Overweight → Neutral
Oct-30-23	Downgrade	Stifel	Buy → Hold
Sep-06-23	Upgrade	Berenberg	Hold → Buy
Jul-14-23	Initiated	HSBC Securities	Buy
Apr-28-23	Downgrade	Deutsche Bank	Hold → Sell
Mar-27-23	Upgrade	Barclays	Equal Weight → Overweight
Dec-13-22	Resumed	Morgan Stanley	Overweight
Aug-12-22	Upgrade	Deutsche Bank	Sell → Hold
Aug-09-22	Downgrade	UBS	Buy → Neutral
May-23-22	Initiated	SVB Leerink	Outperform
Sep-27-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jan-15-21	Initiated	Deutsche Bank	Sell
Sep-29-20	Initiated	Berenberg	Hold
Mar-17-20	Upgrade	Barclays	Underweight → Equal Weight
Mar-11-20	Upgrade	Goldman	Neutral → Buy
Feb-11-20	Initiated	SVB Leerink	Mkt Perform
Jan-06-20	Upgrade	JP Morgan	Neutral → Overweight
Sep-23-19	Upgrade	Guggenheim	Neutral → Buy
Sep-20-19	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-03-19	Initiated	Bernstein	Outperform
Aug-14-19	Upgrade	UBS	Neutral → Buy
Dec-11-18	Upgrade	Jefferies	Hold → Buy
Nov-01-18	Upgrade	Barclays	Underweight → Equal Weight
Oct-09-18	Initiated	Guggenheim	Neutral
Sep-10-18	Upgrade	BofA/Merrill	Neutral → Buy
Aug-10-18	Upgrade	Citigroup	Neutral → Buy
Mar-23-18	Upgrade	Liberum	Hold → Buy
Jan-23-18	Downgrade	Barclays	Equal Weight → Underweight
Dec-06-17	Downgrade	BofA/Merrill	Buy → Neutral
Dec-01-17	Downgrade	Morgan Stanley	Overweight → Underweight
Nov-15-17	Upgrade	Barclays	Underweight → Equal Weight
Aug-30-17	Upgrade	HSBC Securities	Reduce → Hold